{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:30:32Z","timestamp":1791174632534,"version":"4.1.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,6,1]]},"abstract":"<jats:p>R115777 is a nonpeptidomimetic enzyme-specific inhibitor of farnesyl protein transferase (FT) that was developed as a potential inhibitor of Ras protein signaling, with antitumor activity in preclinical models. This study was a phase 1 trial of orally administered R115777 in 35 adults with poor-risk acute leukemias. Cohorts of patients received R115777 at doses ranging from 100 mg twice daily (bid) to 1200 mg bid for up to 21 days. Dose-limiting toxicity occurred at 1200 mg bid, with central neurotoxicity evidenced by ataxia, confusion, and dysarthria. Non\u2013dose-limiting toxicities included reversible nausea, renal insufficiency, polydipsia, paresthesias, and myelosuppression. R115777 inhibited FT activity at 300 mg bid and farnesylation of FT substrates lamin A and HDJ-2 at 600 mg bid. Extracellular signal-regulated kinase (ERK), an effector enzyme of Ras-mediated signaling, was detected in its phosphorylated (activated) form in 8 (36.4%) of 22 pretreatment marrows and became undetectable in 4 of those 8 after one cycle of treatment. Pharmacokinetics revealed a linear relationship between dose and maximum plasma concentration or area under the curve over 12 hours at all dose levels. Weekly marrow samples demonstrated that R115777 accumulated in bone marrow in a dose-dependent fashion, with large increases in marrow drug levels beginning at 600 mg bid and with sustained levels throughout drug administration. Clinical responses occurred in 10 (29%) of the 34 evaluable patients, including 2 complete remissions. Genomic analyses failed to detect N-ras gene mutations in any of the 35 leukemias. The results of this first clinical trial of a signal transduction inhibitor in patients with acute leukemias suggest that inhibitors of FT may have important clinical antileukemic activity.<\/jats:p>","DOI":"10.1182\/blood.v97.11.3361","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T08:46:47Z","timestamp":1027759607000},"page":"3361-3369","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":374,"title":["Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial"],"prefix":"10.1182","volume":"97","author":[{"given":"Judith E.","family":"Karp","sequence":"first","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"End","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees","family":"Bol","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Horak","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Tidwell","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Liesveld","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kottke","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Ange","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi","family":"Buddharaju","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Edward","family":"Highsmith","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Belly","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond J.","family":"Hohl","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Rybak","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Thibault","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"From the University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; University of Rochester Cancer Center, Rochester, New York; Mayo Clinic, Rochester, Minnesota; Janssen Research Foundation, Beerse, Belgium and Spring House, PA; National Cancer Institute, Bethesda, Maryland; and Ortho Clinical Diagnostics, Rochester, NY; University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217094035600_B1","first-page":"4116","article-title":"Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.","volume":"93","author":"Buchner","year":"1999","journal-title":"Blood."},{"key":"2020021217094035600_B2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199812033392301","article-title":"Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the managemenet of acute myeloid leukemia in first remission.","volume":"339","author":"Cassileth","year":"1998","journal-title":"N Engl J Med."},{"key":"2020021217094035600_B3","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood.V74.5.1499.1499","article-title":"A two-step timed sequential treatment for acute myelogenous leukemia.","volume":"74","author":"Geller","year":"1989","journal-title":"Blood."},{"key":"2020021217094035600_B4","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.","volume":"88","author":"Weick","year":"1996","journal-title":"Blood."},{"key":"2020021217094035600_B5","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/sj.leu.2401544","article-title":"Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period.","volume":"13","author":"Baudard","year":"1999","journal-title":"Leukemia."},{"key":"2020021217094035600_B6","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1200\/JCO.1999.17.11.3569","article-title":"Management of acute myeloid leukemia in elderly patients.","volume":"17","author":"Hiddemann","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021217094035600_B7","first-page":"103","article-title":"The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention.","volume":"24","author":"Karp","year":"1997","journal-title":"Semin Oncol."},{"key":"2020021217094035600_B8","first-page":"47","article-title":"Leukemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure.","volume":"19","author":"Levine","year":"1992","journal-title":"Semin Oncol."},{"key":"2020021217094035600_B9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V85.5.1151.bloodjournal8551151","article-title":"The biology and treatment of acute lymphoblastic leukemia in adults.","volume":"85","author":"Copelan","year":"1995","journal-title":"Blood."},{"key":"2020021217094035600_B10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B cell acute lymphoblastic leukemia.","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood."},{"key":"2020021217094035600_B11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lympyhocytic leukemia.","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020021217094035600_B12","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V80.12.2983.2983","article-title":"Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study (8762).","volume":"80","author":"Westbrook","year":"1992","journal-title":"Blood."},{"key":"2020021217094035600_B13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nm0496-403","article-title":"Drug development train gathering steam.","volume":"2","author":"Ito","year":"1996","journal-title":"Nat Med."},{"key":"2020021217094035600_B14","first-page":"657","article-title":"Acute leukemia: mechanisms of cell survival as targets for therapy (review).","volume":"11","author":"Karp","year":"1997","journal-title":"Int J Oncol."},{"key":"2020021217094035600_B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.leu.2401657","article-title":"Serine\/threonine phosphorylation in cytokine signal transduction.","volume":"14","author":"McCubrey","year":"2000","journal-title":"Leukemia."},{"key":"2020021217094035600_B16","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood.V94.9.2971","article-title":"Ras proteins: recent advances and new functions.","volume":"94","author":"Rebollo","year":"1999","journal-title":"Blood."},{"key":"2020021217094035600_B17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/363045a0","article-title":"Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation.","volume":"363","author":"Egan","year":"1993","journal-title":"Nature."},{"key":"2020021217094035600_B18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/363085a0","article-title":"Guanine nucleotide-releasing factor hSos1 binds to Grb2 and links tyrosine kinases to Ras signalling.","volume":"363","author":"Li","year":"1993","journal-title":"Nature."},{"key":"2020021217094035600_B19","doi-asserted-by":"crossref","first-page":"32621","DOI":"10.1016\/S0021-9258(18)31679-X","article-title":"The signalling pathway coupling epidermal growth factor receptors to activation of p21ras.","volume":"51","author":"Sasaoka","year":"1994","journal-title":"J Biol Chem."},{"key":"2020021217094035600_B20","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1126\/science.275.5307.1750","article-title":"Protein prenylation, et cetera: signal transduction in two dimensions.","volume":"27","author":"Gelb","year":"1997","journal-title":"Science."},{"key":"2020021217094035600_B21","first-page":"461","article-title":"Protein prenylation: key to ras function and cancer intervention.","volume":"3","author":"Khosvari-Far","year":"1992","journal-title":"Cell Growth Diff."},{"key":"2020021217094035600_B22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1006380320290","article-title":"Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.","volume":"17","author":"End","year":"1999","journal-title":"Invest New Drugs."},{"key":"2020021217094035600_B23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1999.17.3.1071","article-title":"RAS and leukemia: from basic mechanisms to gene-directed therapy.","volume":"17","author":"Beaurpe","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021217094035600_B24","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/MCB.19.3.1831","article-title":"Cell growth inhibition by farnesyltransferase inhibitors is mediated by a gain of granylgeranylated Rho B.","volume":"19","author":"Du","year":"1999","journal-title":"Mol Cell Biol."},{"key":"2020021217094035600_B25","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood.V96.5.1655","article-title":"Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies.","volume":"96","author":"Reuter","year":"2000","journal-title":"Blood."},{"key":"2020021217094035600_B26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.onc.1202175","article-title":"Non-Ras tragets of farnesyltransferase inhibitors: focus on Rho.","volume":"17","author":"Lebowitz","year":"1998","journal-title":"Oncogene."},{"key":"2020021217094035600_B27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/MCB.20.1.139-148.2000","article-title":"The phosphoinositide 3-OH kinase\/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.","volume":"20","author":"Jiang","year":"2000","journal-title":"Mol Cel Biol."},{"key":"2020021217094035600_B28","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.V76.6.1214.1214","article-title":"RAS mutations are rare events in Philadelphia chromosome-negative\/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.","volume":"76","author":"Hirsch-Ginsberg","year":"1990","journal-title":"Blood."},{"key":"2020021217094035600_B29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V82.2.590.590","article-title":"N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome.","volume":"82","author":"Paquette","year":"1993","journal-title":"Blood."},{"key":"2020021217094035600_B30","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/jnci\/84.21.1626","article-title":"Ras oncogene activation and occupational exposures in acute myeloid leukemia.","volume":"84","author":"Taylor","year":"1992","journal-title":"J Natl Cancer Inst."},{"key":"2020021217094035600_B31","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V69.4.1237.1237","article-title":"Mutations in N-ras predominate in acute myeloid leukemia.","volume":"69","author":"Bos","year":"1987","journal-title":"Blood."},{"key":"2020021217094035600_B32","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V83.6.1603.bloodjournal8361603","article-title":"Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.","volume":"83","author":"Neubauer","year":"1994","journal-title":"Blood."},{"key":"2020021217094035600_B33","first-page":"1098","article-title":"SSCP detection of N-ras promoter mutations in AML patients.","volume":"23","author":"Thorn","year":"1995","journal-title":"Exp Hematol."},{"key":"2020021217094035600_B34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell."},{"key":"2020021217094035600_B35","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","article-title":"Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.","volume":"13","author":"Puil","year":"1994","journal-title":"EMBO J."},{"key":"2020021217094035600_B36","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","article-title":"Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development.","volume":"17","author":"Rowinsky","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021217094035600_B37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2000.18.4.927","article-title":"Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.","volume":"18","author":"Zujewski","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020021217094035600_B38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol."},{"key":"2020021217094035600_B39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/clinchem\/46.5.620","article-title":"Detection of rare mutant alleles by restriction endonuclease-mediated selective-PCR: assay design and optimization.","volume":"46","author":"Fuery","year":"2000","journal-title":"Clin Chem."},{"key":"2020021217094035600_B40","article-title":"Unusual tight binding of R115777 to farnesyl protein transferase (FPT) allows for ex vivo measurement of FPT inhibition","volume-title":"Proceedings of the American Association for Cancer Research; April 1-5","author":"End","year":"1404"},{"key":"2020021217094035600_B41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding.","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem."},{"key":"2020021217094035600_B42","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/382370a0","article-title":"Role of kinases and the phosphates calcineurin in the nuclear shuttling of transcription factor NF-AT4.","volume":"382","author":"Shibasaki","year":"1996","journal-title":"Nature."},{"key":"2020021217094035600_B43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-642-58259-2_2","article-title":"The Hsp90 chaperone family","volume-title":"Latchman DS eds, Stress Proteins.","author":"Neckers","year":"1999"},{"key":"2020021217094035600_B44","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1083\/jcb.110.5.1489","article-title":"Isoprenylation is required for the processing of the lamin A precursor.","volume":"110","author":"Beck","year":"1990","journal-title":"J Cell Biol."},{"key":"2020021217094035600_B45"},{"key":"2020021217094035600_B46","first-page":"2318","article-title":"Comparison of potential markers of farnesyltransferase inhibition.","volume":"6","author":"Adjei","year":"2000","journal-title":"Clin Cancer Res."},{"key":"2020021217094035600_B47","first-page":"1871","article-title":"A phase 1 trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.","volume":"60","author":"Adjei","year":"2000","journal-title":"Cancer Res."},{"key":"2020021217094035600_B48","first-page":"2847","article-title":"Expression of nuclear envelope lamins A and C in human myeloid leukemias.","volume":"52","author":"Kaufmann","year":"1992","journal-title":"Cancer Res."},{"key":"2020021217094035600_B49","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V89.6.2098","article-title":"Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.","volume":"89","author":"Kaufmann","year":"1997","journal-title":"Blood."},{"key":"2020021217094035600_B50","first-page":"3229","article-title":"An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing.","volume":"54","author":"Sinensky","year":"1994","journal-title":"Cancer Res."},{"key":"2020021217094035600_B51","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/j.1460-2075.1988.tb03073.x","article-title":"Mutations in the nuclear lamin proteins resulting in their aberrant assembly in the cytoplasm.","volume":"7","author":"Loewinger","year":"1988","journal-title":"EMBO J."},{"key":"2020021217094035600_B52","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood.V85.8.1985.bloodjournal8581985","article-title":"Childhood monosomy 7: epidemiology, biology, and mechanistic implications.","volume":"85","author":"Luna-Fineman","year":"1995","journal-title":"Blood."},{"key":"2020021217094035600_B53","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.onc.1201234","article-title":"Raf\/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21 Ras in IL-3 dependent hematopoietic cells.","volume":"15","author":"Kinoshita","year":"1997","journal-title":"Oncogene."},{"key":"2020021217094035600_B54","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.1604323","article-title":"Nerve growth factor stimulation of the Ras-guanine nucleotide exchange factor and GAP activties.","volume":"256","author":"Li","year":"1992","journal-title":"Science."},{"key":"2020021217094035600_B55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0006-8993(99)01643-1","article-title":"Nerve growth factor-induced PKB\/Akt activity is sustained by phosphoinositide 3-kinase dependent and independent signals in sympathetic neurons.","volume":"837","author":"Virdee","year":"1999","journal-title":"Brain Res."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/11\/3361\/1674354\/h8110103361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/11\/3361\/1674354\/h8110103361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T05:21:06Z","timestamp":1622006466000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/11\/3361\/107528\/Clinical-and-biologic-activity-of-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,1]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.11.3361","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6,1]]}}}